Clinical Trials
10 trialsNCT04996875 2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT03328078 2026-04-16
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Phase 1/2 Recruiting
NCT07216443 2026-04-15
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Phase 2 Recruiting
NCT03207854 2026-04-02
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
University of Southern California
Recruiting
NCT05969821 2026-03-23
CHIS
Assistance Publique - Hôpitaux de Paris
Not yet recruiting
NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT03016377 2025-10-27
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting
NCT05963217 2025-07-02
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
Phase 1 Recruiting